PL3765055T3 - Peptydy wiążące bakterie do leczenia chorób zakaźnych i powiązanych procesów zapalnych - Google Patents

Peptydy wiążące bakterie do leczenia chorób zakaźnych i powiązanych procesów zapalnych

Info

Publication number
PL3765055T3
PL3765055T3 PL19710418.5T PL19710418T PL3765055T3 PL 3765055 T3 PL3765055 T3 PL 3765055T3 PL 19710418 T PL19710418 T PL 19710418T PL 3765055 T3 PL3765055 T3 PL 3765055T3
Authority
PL
Poland
Prior art keywords
bacterial
treatment
infectious diseases
binding peptides
inflammatory processes
Prior art date
Application number
PL19710418.5T
Other languages
English (en)
Inventor
Francisco Lozano Soto
Mario MARTÍNEZ FLORENSA
Original Assignee
Sepsia Therapeutics, S.L.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sepsia Therapeutics, S.L. filed Critical Sepsia Therapeutics, S.L.
Publication of PL3765055T3 publication Critical patent/PL3765055T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08Peptides having 5 to 11 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177Receptors; Cell surface antigens; Cell surface determinants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • External Artificial Organs (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL19710418.5T 2018-03-13 2019-03-13 Peptydy wiążące bakterie do leczenia chorób zakaźnych i powiązanych procesów zapalnych PL3765055T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18382164 2018-03-13
PCT/EP2019/056315 WO2019175261A1 (en) 2018-03-13 2019-03-13 Bacterial-binding peptides for treatment of infectious diseases and related inflammatory processes

Publications (1)

Publication Number Publication Date
PL3765055T3 true PL3765055T3 (pl) 2023-11-27

Family

ID=61768231

Family Applications (1)

Application Number Title Priority Date Filing Date
PL19710418.5T PL3765055T3 (pl) 2018-03-13 2019-03-13 Peptydy wiążące bakterie do leczenia chorób zakaźnych i powiązanych procesów zapalnych

Country Status (11)

Country Link
US (2) US11660326B2 (pl)
EP (1) EP3765055B9 (pl)
JP (1) JP7792115B2 (pl)
AU (1) AU2019233613B2 (pl)
CA (1) CA3133008A1 (pl)
ES (1) ES2953362T3 (pl)
HR (1) HRP20230984T1 (pl)
HU (1) HUE062829T2 (pl)
PL (1) PL3765055T3 (pl)
RS (1) RS64455B1 (pl)
WO (1) WO2019175261A1 (pl)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017360043A1 (en) * 2016-11-18 2019-06-20 Hospital Clinic De Barcelona Combined CD6 and imipenem therapy for treatment of infectious diseases and related inflammatory processes
EP4272837A3 (en) 2019-08-02 2024-02-28 Fundacio de Recerca Clinic Barcelona-Institut d'Investigacions Biomèdiques August Pi I Sunyer Car t-cells against bcma for the treatment of multiple myeloma
US10881781B1 (en) 2020-04-29 2021-01-05 Orth Consulting, Llc Blood processing apparatus and method for detoxifying bacterial lipopolysaccharide

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003530838A (ja) * 2000-04-12 2003-10-21 ヒューマン ゲノム サイエンシズ インコーポレイテッド アルブミン融合タンパク質
WO2008119851A1 (es) 2007-03-28 2008-10-09 Universidad De Barcelona Producto proteico para el tratamiento de enfermedades infecciosas y procesos inflamatorios relacionados
JP2014516046A (ja) * 2011-05-26 2014-07-07 フンダシオ・クリニック・ペル・ア・ラ・レセルカ・ビオメディカ がん若しくは腫瘍の治療用の又はアジュバントとして使用される可溶性タンパク質cd5又はcd6
DK3221313T3 (en) 2014-11-17 2019-04-08 Entasis Therapeutics Ltd COMBINATION THERAPY FOR TREATING INFECTIONS WITH RESISTANT BACTERIA
WO2018025052A1 (en) 2016-08-04 2018-02-08 Oxford University Innovation Limited Chimeric antigen receptors
AU2017360043A1 (en) 2016-11-18 2019-06-20 Hospital Clinic De Barcelona Combined CD6 and imipenem therapy for treatment of infectious diseases and related inflammatory processes

Also Published As

Publication number Publication date
AU2019233613A1 (en) 2020-10-29
HUE062829T2 (hu) 2023-12-28
RS64455B1 (sr) 2023-09-29
JP7792115B2 (ja) 2025-12-25
ES2953362T3 (es) 2023-11-10
EP3765055B9 (en) 2023-09-27
EP3765055B1 (en) 2023-06-07
EP3765055A1 (en) 2021-01-20
HRP20230984T1 (hr) 2023-12-08
US20210023162A1 (en) 2021-01-28
AU2019233613B2 (en) 2025-02-13
CA3133008A1 (en) 2019-09-19
EP3765055C0 (en) 2023-06-07
US11660326B2 (en) 2023-05-30
JP2021518426A (ja) 2021-08-02
US20230381266A1 (en) 2023-11-30
WO2019175261A1 (en) 2019-09-19

Similar Documents

Publication Publication Date Title
IL285269A (en) Compositions and methods for treating neurocognitive disorders
IL272410A (en) Cytokine conjugates for the treatment of autoimmune diseases
IL280563A (en) Anti-btn3a antibodies and their use in treating cancer or infectious disorders
IL269158A (en) Compositions and methods for treating inflammatory diseases
IL285270A (en) Compositions and methods for treating neurocognitive disorders
IL284125A (en) Quinoline derivatives for use in the treatment of inflammation diseases
IL263174A (en) Compositions comprising cannabidiol and hyaluronic acid for treating inflammatory joint diseases
PL3600309T3 (pl) Skojarzenia terapeutyczne do leczenia chorób wątroby
EP3359171C0 (en) Use of akkermansia muciniphila for treating inflammatory conditions
EP3538548A4 (en) IL-2 VARIANTS FOR THE TREATMENT OF AUTOIMMUNE DISEASES
DK3347030T3 (da) Brug af pasteuriseret akkermansia til behandling af stofskiftesygdomme
PL3774897T3 (pl) Sposoby i układ do selekcji i leczenia pacjentów z chorobami zapalnymi
MA49413A (fr) Traitement de gaz acide
IL273705B (en) Benzothiazol compounds and methods using the same for treating neurodegenerative disorders
IL287796A (en) Compositions and methods for the treatment of atpase-mediated diseases
EP3713955A4 (en) ANTI-IFNAR1 ANTIBODIES FOR THE TREATMENT OF AUTOIMMUNE DISEASES
IL264070A (en) Methods and compositions for treatment of disorders and diseases involving rdh12
ZA202101587B (en) Protein for treatment of inflammatory diseases
IL291192A (en) Compositions and methods of treating lupus nephritis
IL289371A (en) Methylthioninium for use in the treatment of synaptopathies
PL3765055T3 (pl) Peptydy wiążące bakterie do leczenia chorób zakaźnych i powiązanych procesów zapalnych
IL285268A (en) Compositions and methods for treating neurocognitive disorders
IL283039A (en) Immunogenic compositions for treatment of hepatitis b
DK3229827T3 (da) Modificerede peptider og anvendelse deraf til behandling af kroniske inflammatoriske sygdomme
EP4081250A4 (en) ALLERGY TREATMENT